This site is intended for health professionals only

Novartis highlights research success


Novartis has highlighted the success of its pharmaceuticals research strategy in delivering novel compounds to the clinic, reflecting the benefits of sustained investments in Research and Development.

A total of 88 New Molecular Entities (NMEs) are in the exploratory pipeline, a 40% increase since 2005. Highlighting improved productivity, 80% of compounds that were successful in Proof-of-Concept clinical trials in 2006-2007 have been transitioned to confirmatory phase II/III trials. This is a 60% improvement from trials during 2003-2005.

The priority of drug discovery efforts are in diseases where there is greatest patient need coupled with strong molecular understanding of the disease. Homogeneous populations, defined either as a genetic disease or by biomarkers, provide the pathway to the clinic. This approach has improved the success rate from exploratory to confirmatory clinical development.

“Our strategy is working to deliver more effective medicines to patients rapidly,” said Mark Fishman, President of the Novartis Institutes for BioMedical Research. “In a relatively short time we have dramatically increased the size and power of our pipeline and believe many of these compounds have the potential to change the practice of medicine.”

For the full press release on Novartis, click the link below:



Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine